Blacks with muscular dystrophy die 10-12 years younger than whites: New study

	Tweet

African Americans with muscular dystrophy die 10 to 12 years younger than their white counterparts, according to research published in the Sept. 14 issue of Neurology, the medical journal of the American Academy of Neurology.

The black-white mortality gap, which was calculated on the basis of 20 years of data, is among the largest ever observed in the annals of research into racial disparities in health care, say Dr. Nicte Mejia and Dr. Rachel Nardin, co-authors of the editorial. “Furthermore,” they write, “white patients with MD [muscular dystrophy] enjoy increasing survival, while survival of black patients with MD barely budges,” leading to an ongoing widening of that gap.

Muscular dystrophy is a group of inherited muscle diseases that lead to early death due to respiratory or cardiac failure. Various types of MD affect about 50,000 Americans.

"Inequities in the health delivery system – and the multiple ways in which race constrains access to care – seem the most likely explanation for the observed MD black-white mortality gap,” Mejia and Nardin write in their editorial. But they add that inadequate access to care due to lack of good quality health insurance may also be part of the picture.

“Nonelderly African Americans are 1.5 times more likely than whites to lack any type of insurance and about twice as likely to rely on Medicaid,” they write, noting that lack of health insurance is linked to lack of access to care.

And while Medicaid, the public health program for the poor, compares favorably with private insurance in providing access to primary care, it falls short when it comes to providing access to the standard-of-care treatments needed to manage conditions like muscular dystrophy, they say.

These shortcomings of Medicaid coverage are “particularly worrisome because more than half of the new health coverage under the 2010 National Health Reform will be Medicaid.”

In a separate comment made today, Nardin said, “Replacing the current U.S. health care financing system with a single-payer system that would ensure comprehensive insurance coverage for every American, regardless of race, would go a long way toward reducing this type of disparity.”

###

Mejia and Nardin’s editorial, titled “Dying young: Eliminating racial disparities in neuromuscular disease outcomes,” is based on a research paper by Aileen Kenneson, Ph.D., Ajay Vatave, M.D., and Richard Finkel, M.D., titled “Widening Gap in age at muscular dystrophy-associated death between black and whites, 1986-2005,” which is being published simultaneously in the same issue of Neurology, the world’s leading clinical neurology journal. For a copy of the EMBARGOED research study, visit http://www.aan.com/go/pressroom.

A copy of the EMBARGOED editorial is available from Physicians for a National Health Program.

Physicians for a National Health Program (http://www.pnhp.org) is an organization of more than 17,000 doctors who support single-payer national health insurance. PNHP had no role in funding or otherwise influencing the articles mentioned above. To speak with a physician/spokesperson in your area, visit http://www.pnhp.org/stateactions or call (312) 782-6006.

Physicians for a National Health Program
29 E. Madison St., Suite 602
Chicago IL 60602
(312) 782-6006
http://www.pnhp.org

###

Contact: Mark Almberg

312-782-6006
Physicians for a National Health Program

RELATED STORIES:
Smoking Increase Risk of age-related macular degeneration   Antibody May Reverse Some Alzheimer’s Symptoms   Diabetes drug shows promise in multiple sclerosis   Alzheimer’s disease: Definition, Diagnosis, Prevention and Treatment   Milestone for cannabinoid MS study   Stroke risk rises if stroke survivors stop aspirin   Study links restless leg syndrome with erectile dysfunction in older men   Parkinson’s-Alzheimer’s link seen unlikely   MS drug prevented fatal heart condition in lab study   Alzheimer’s Disease Linked to Mitochondrial Damage   Discovery of genetic mutation in Leigh syndrome   Possible target for future therapies aimed at delaying or stopping Alzheimer’s disease

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]